Denali Therapeutics Inc.

DNLI· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$23.15+0.56%

2026-08-03

Financials

Valuation Metrics

Denali Therapeutics Inc.'s Market Cap is $3.67B. At end of 2025 it was $2.90B. Ranked #1621 of 3,111 in US market (top 52%), #568 of 1,445 on NASDAQ (top 39%), #92 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 34%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$3.67B	US#1,621/3,111 Sec#92/269
Revenue	$0.00	US#2,980/3,111 Sec#205/269
Net Income	$-508M	US—/3,111 Sec—/269
Total Assets	$1.27B	US#2,341/3,111 Sec#85/269
Net Assets	$926M	US#1,835/3,111 Sec#70/269
Value
P/B	3.97x	US#1,985/3,111 Sec#120/269
FCF Yield	-11.41%	US—/3,111 Sec—/269
Profitability
ROE	-54.86%	US#2,762/3,111 Sec#182/269
ROA	-40.13%	US#2,936/3,111 Sec#194/269
Financial Health
Debt Ratio	36.71%	US#419/3,111 Sec#120/269
Total Debt	$40M	US#2,616/3,111 Sec#157/269
FCF	$-419M	US#2,831/3,111 Sec#256/269
Cash	$388M	US#1,251/3,111 Sec#70/269
Current Ratio	9.28x	US#265/3,111 Sec#88/269
Performance
1Y Return	72.25%	US#511/3,111 Sec#104/269
1M Return	-10.38%	US#2,553/3,111 Sec#192/269
From 52W High	-15.20%	US#1,390/3,111 Sec#91/269
1Y MDD	-20.49%	US#719/3,111 Sec#30/269
Trading
Volume	1,440,153 shares	US#1,255/3,111 Sec#116/269
Trading Value	$33M	US#1,705/3,111 Sec#115/269
Per Share
EPS	$-2.92	US—/3,111 Sec—/269
BPS	$5.78	US#2,158/3,111 Sec#120/269